Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by jakethesnake2on Jul 23, 2014 11:07am
384 Views
Post# 22773594

Puma Biotechnology shares more than triple on postive trial

Puma Biotechnology shares more than triple on postive trial


We all hope that PLI will have its day in the sun soon.




NEW YORK (MarketWatch) -- Shares of Puma Biotechnology PBYI+278.06% more than tripled in after-hours trade Tuesday after the company reported positive results from a late-stage trial of its breast cancer treatment. The company said use of its investigational drug resulted in a 33% improvement in disease-free survival, which was the Phase 3 trial's primary endpoint, when compared with a placebo. The stock was trading at $194.89, compared with Tuesday's closing price of $59.03, and the all-time closing high of $139.92 hit on Jan. 21, 2014. After-hours volume had already exceeded the regular-session daily average of about 382,000 share.

Regards
Jack
Bullboard Posts